Blasts Under 5 Percent of Peripheral Blood White Cells
1 clinical trials · Condition
◉ Watch Blasts Under 5 Percent of Peripheral Blood White Cells
| Record | Firm | Date |
|---|---|---|
| Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation (NCT03881735) | Roswell Park Cancer Institute | 2019-12-02 |
Track Blasts Under 5 Percent of Peripheral Blood White Cells automatically
Every clearance here is in the API, with alerts when new ones post.